| Name | Title | Contact Details |
|---|
Parker Medical Inc is a Bridgewater, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MPRO is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Fewer than 50% of Sleep Apnea patients stick with a CPAP solution – including us. So we decided to do something about it. Not sleeping sucks. Not sleeping and spending a fortune on CPAP devices that leak, fall off or leave marks on your face sucks even worse. That`s why we invented the DreamPort Sleep Solution – the world`s first-ever maskless CPAP device. The result is the smallest, lightest, most ergonomically accommodating CPAP solution on the market – a device that fits comfortably and doesn`t restrict your movement – enabling patients to get a better night`s sleep. Our goal is simple – to make the best bleeping CPAP products on the planet. We won`t stop until every sleep apnea patient is sleeping like a baby.
Karl Storz - Endoskope is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.
At LumiThera, we are committed to developing solutions to prevent vision loss and blindness, improve visual function and stop or slow the progression of blinding diseases of the eye. We will continue to innovate non-invasive approaches to address unmet medical needs. LumiThera, Inc. is a commercial-stage medical device company initially focused on treating patients affected by dry age-related macular degeneration. The Company`s expertise is in the application of photobiomodulation (“PBM”), using non-invasive light emitting diodes (“LED”) for acute and chronic ocular diseases and disorders. The Company is developing an ophthalmic LED office-based instrument to be used in multiple ocular conditions or disorders as non-invasive medical treatments. Three clinical studies have demonstrated clinical and pathological benefits of PBM in treating subjects with dry AMD. The recent TORPA II clinical trial results demonstrating improvements in clinical outcomes of vision and reduction of pathological “drusen” following imaging analysis were published in December 2016 in ACTA Ophthalmologica, a top peer-reviewed Ophthalmology journal. The company recently completed the LIGHTSITE I clinical trial,a thirty subject dry AMD study partially supported by the National Eye Institute. The Valeda LIght Delivery System is now available for sale in the European Economic Area. The Valeda Light Delivery System is CE Marked. The device is not for sale in the USA.